PharmaMar's Zepsyre misses in first Phase III trial

PharmaMar S.A. (Madrid:PHM) lost €0.88 (34%) to €1.70 on Friday after reporting that Zepsyre lurbinectedin (PM1183) missed the primary endpoint of improving progression-free survival (PFS) vs. topotecan or pegylated liposomal doxorubicin in the Phase III CORAIL trial to treat platinum-resistant ovarian cancer. The company said PFS was the same in all three treatment arms, but did not disclose details or next steps. Data are slated to be presented at a future cancer conference.

In October, President and CEO José María Fernández Sousa-Faro told BioCentury he believed Zepsyre could be a blockbuster drug, mostly due to its potential in small cell lung cancer (SCLC) and endometrial cancer...